Pharmacokinetics and pharmacodynamics of intravenous agents for ventricular arrhythmias.
Although no antiarrhythmic agent has ideal pharmacokinetic and pharmacodynamic characteristics, it is useful to evaluate antiarrhythmic agents in terms this ideal profile. The most desirable characteristics of an intravenous antiarrhythmic agent for treating ventricular arrhythmias are outlined. The basic pharmacokinetic and pharmacodynamic properties of the most commonly used agents for this indication-including amiodarone, bretylium, lidocaine, procainamide, and quinidine-are also reviewed, in light of this profile.
Nolan
P E
PE
Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson 85721-0207, USA.
D000638:Amiodarone / Q000493:pharmacokinetics / Q000494:pharmacology; D000889:Anti-Arrhythmia Agents / Q000493:pharmacokinetics* / Q000494:pharmacology*; D001711:Biotransformation; D001949:Bretylium Compounds / Q000493:pharmacokinetics / Q000494:pharmacology; D004562:Electrocardiography / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008012:Lidocaine / Q000493:pharmacokinetics / Q000494:pharmacology; D011342:Procainamide / Q000493:pharmacokinetics / Q000494:pharmacology; D011802:Quinidine / Q000493:pharmacokinetics / Q000494:pharmacology; D017180:Tachycardia, Ventricular / Q000188:drug therapy*; D014693:Ventricular Fibrillation / Q000188:drug therapy*
D000889:Anti-Arrhythmia Agents; D001949:Bretylium Compounds; D008012:Lidocaine; D011802:Quinidine; D011342:Procainamide; D000638:Amiodarone; C045166:bretylium